NCT05515627View on ClinicalTrials.gov

Atezolizumab for Idiopathic Pulmonary Fibrosis

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks

Trial Locations (1)

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER